Prescient Therapeutics moves PTX-100 further in Phase 2a trial
Prescient Therapeutics says PTX-100 is being evaluated in a Phase 2a trial for Cutaneous T-Cell Lymphoma (CTCL).
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.